Transplants and Implants Clinical Trial
Official title:
B-Cell Targeted Desensitization With Carfilzomib for Preformed Anti-HLA Antibodies in Patients Awaiting Kidney Transplantation
The primary purpose of this study is to provide a preliminary evaluation of the safety and potential efficacy of carfilzomib in reducing HLA antibody levels in highly sensitized kidney transplant candidates.
This study is a non-randomized, open label, iterative pilot study. The duration of study will include a 16 month enrollment period and 5 to 6 months of follow-up. A total of 32 patients, male and female, between the ages 18 to 65 will be enrolled. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00771745 -
Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients
|
Phase 4 | |
| Terminated |
NCT00596947 -
Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant
|
Phase 4 | |
| Recruiting |
NCT01800929 -
Evaluation of Performance and Usability of N6 in the Paediatric Population
|
N/A | |
| Terminated |
NCT00522548 -
Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients
|
Phase 4 | |
| Recruiting |
NCT02522572 -
Quantitating the Impact of Plerixafor
|
Phase 1/Phase 2 |